Predicting acute and persistent neuropathy associated with oxaliplatin

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 4, 2013, Pages 331-337

  Alejandro, Linh M ^a,b   Behrendt, Carolyn E ^a   Chen, Kim ^a   Openshaw, Harry ^a   Shibata, Stephen ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

Author keywords

adjuvant chemotherapy; colonic neoplasms drug therapy; organoplatinum compounds adverse effects; peripheral nervous system diseases chemically induced; risk factors

Indexed keywords

BEVACIZUMAB; OXALIPLATIN;

ADULT; ARM INJURY; BODY SURFACE; BODY WEIGHT; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE DURATION; DRUG TOLERABILITY; FEMALE; FIBROMYALGIA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; PERIPHERAL NEUROPATHY; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; COHORT STUDIES; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; PYRIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881023328     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318246b50d     Document Type: Conference Paper

References (29)

1. Park SB, Goldstein D, CS-Y Lin, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neuro-toxicity. J Clin Oncol. 2009;27:1243-1249.
2. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009;132:2712-2723.
3. Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29: 21-33.
4. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51-60.
5. Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol. 2006;56:13-16.
6. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leuco-vorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25:2205-2211.
7. Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507-1515.
8. Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29: 421-427.
9. Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol. 2008;26(suppl):180s. (Abstract 4010).
10. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
11. Grothey A. Clinical management of oxaliplatin-associated neuro-toxicity. Clin Colorectal Cancer. 2005;5(suppl 1):S38-S46.
12. Kanbayashi Y, Hosokawa T, Okamoto K, et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincris-tine using ordered logistic regression analysis. Anti-Cancer Drugs. 2010;21:877-881.
13. Lecomte T, Landi B, Beaune P, et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006;12:3050-3056.
14. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25:1247-1254.
15. McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010;28: 3227-3233.
16. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
17. Sanofi Aventis. Eloxatin (oxaliplatin powder) full prescribing information. Available at: http://products.sanofi-aventis.us/eloxatin/eloxatin. html. Accessed November 8, 2010.
18. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics. 2001;57:120-125.
19. Preisser JS, Qaqish BF. Deletion diagnostics for generalised estimating equations. Biometrika. 1996;83:551-562.
20. Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205-1218.
21. Takimoto CH, Graham MA, Lockwood G, et al. Oxali-platin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13: 4832-4839.
22. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45:157-164.
23. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
24. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26:3523-3529.
25. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol. 2006;24:394-400.
26. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27:5727-5733.
27. Nishioka M, Shimada M, Kurita N, et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol. 2011;16:322-327.
28. Kono T, Mamiya N, Chisato N, et al. Efficacy of Goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colon cancer. Evid Based Complement Alternat Med. 2011;2011: Article ID 418481, 8 pages.
29. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23:4866-4875.